🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/10/2002 | 18,15 | 18,85 | 17,80 | 18,18 | -0,38% | 5,79% | 698.500 |
| 02/10/2002 | 19,56 | 19,95 | 18,06 | 18,25 | -6,70% | 9,66% | 738.000 |
| 01/10/2002 | 18,96 | 19,86 | 18,17 | 19,56 | +5,79% | 8,91% | 907.700 |
| 30/09/2002 | 18,49 | 19,35 | 17,27 | 18,49 | -0,38% | 11,25% | 972.400 |
| 27/09/2002 | 19,57 | 20,00 | 18,39 | 18,56 | -3,38% | 8,23% | 1.127.000 |
| 26/09/2002 | 18,75 | 19,37 | 18,12 | 19,21 | +2,89% | 6,67% | 919.100 |
| 25/09/2002 | 18,00 | 19,29 | 17,88 | 18,67 | +4,77% | 7,83% | 743.000 |
| 24/09/2002 | 16,09 | 18,48 | 15,76 | 17,82 | +9,06% | 16,90% | 1.349.900 |
| 23/09/2002 | 17,33 | 17,45 | 15,75 | 16,34 | -6,52% | 9,81% | 843.800 |
| 20/09/2002 | 17,00 | 18,36 | 17,00 | 17,48 | -2,40% | 8,00% | 868.900 |
| 19/09/2002 | 18,78 | 18,84 | 17,83 | 17,91 | -5,24% | 5,38% | 838.800 |
| 18/09/2002 | 18,65 | 19,30 | 17,89 | 18,90 | +0,16% | 7,56% | 767.400 |
| 17/09/2002 | 19,79 | 20,31 | 18,77 | 18,87 | -3,43% | 7,78% | 518.900 |
| 16/09/2002 | 19,72 | 19,90 | 18,70 | 19,54 | -0,96% | 6,09% | 518.200 |
| 13/09/2002 | 19,51 | 20,10 | 19,12 | 19,73 | +0,87% | 5,02% | 455.600 |
| 12/09/2002 | 20,28 | 20,44 | 19,45 | 19,56 | -3,69% | 4,88% | 334.600 |
| 11/09/2002 | 20,63 | 21,15 | 20,26 | 20,31 | +0,54% | 4,31% | 330.400 |
| 10/09/2002 | 19,86 | 20,61 | 19,43 | 20,20 | +1,05% | 5,94% | 760.700 |
| 09/09/2002 | 19,07 | 20,22 | 18,20 | 19,99 | +4,88% | 10,59% | 618.700 |
| 06/09/2002 | 18,27 | 19,53 | 18,25 | 19,06 | +5,01% | 7,01% | 826.700 |
| 05/09/2002 | 19,18 | 19,25 | 18,12 | 18,15 | -5,96% | 5,89% | 483.700 |
| 04/09/2002 | 18,59 | 19,60 | 18,12 | 19,30 | +4,04% | 7,96% | 908.300 |
| 03/09/2002 | 19,85 | 19,86 | 18,26 | 18,55 | -6,78% | 8,06% | 664.500 |
| 30/08/2002 | 21,40 | 21,53 | 19,90 | 19,90 | -6,57% | 7,62% | 561.300 |
| 29/08/2002 | 20,20 | 21,44 | 19,85 | 21,30 | +3,40% | 7,87% | 1.083.700 |
| 28/08/2002 | 21,14 | 21,15 | 20,14 | 20,60 | -2,97% | 4,78% | 634.600 |
| 27/08/2002 | 22,46 | 22,68 | 21,11 | 21,23 | -5,14% | 6,99% | 547.400 |
| 26/08/2002 | 22,54 | 22,57 | 20,86 | 22,38 | -0,13% | 7,59% | 625.100 |
| 23/08/2002 | 22,90 | 23,22 | 22,41 | 22,41 | -2,57% | 3,54% | 584.300 |
| 22/08/2002 | 23,65 | 23,80 | 22,33 | 23,00 | -2,87% | 6,22% | 1.577.300 |